婴幼儿唾液中三种免疫学指标与贫血关系的研究

[目的]了解正常儿童唾液中sIgA、IL-6与TNF-α的含量及其相互关系,探讨其与婴幼儿贫血的关系.[方法]采取随机整群抽样的方法对陕西农村391名出生至18个月婴幼儿进行调查,并对其中55名婴幼儿采用ELISA方法检测唾液中sIgA、IL-6与TNF-α的含量,并对贫血与非贫血组儿童唾液中三种免疫指标含量进行比较.[结果]O～18个月龄的婴幼儿sIgA、IL-6与TNF-α的均数随年龄增大而变化的趋势基本一致,在4～6月中均为最高,1岁后趋于平稳;贫血组的唾液sIgA低于非贫血组,而唾液TNF-a和IL-6均高于非贫血组.[结论]O～18个月龄的婴幼儿唾液中sIgA水平较低,唾液IL-6、TNF-α榆测可考虑作为贫血患者的免疫监测指标.     

Proteomic Approaches for Biomarker Panels in Cancer

Proteomic technologies remain the main backbone of biomarkers discovery in cancer. The continuous development of proteomic technologies also enlarges the bioinformatics domain, thus founding the main pillars of cancer therapy. The main source for diagnostic/prognostic/therapy monitoring biomarker panels are molecules that have a dual role, being both indicators of disease development and therapy targets.

Proteomic technologies, such as mass-spectrometry approaches and protein array technologies, represent the main technologies that can depict these biomarkers. Herein, we will illustrate some of the most recent strategies for biomarker discovery in cancer, including the development of immune-markers and the use of cancer stem cells as target therapy.

The challenges of proteomic biomarker discovery need new forms of cross-disciplinary conglomerates that will result in increased and tailored access to treatments for patients; diagnostic companies would benefit from the enhanced co-development of companion diagnostics and pharmaceutical companies.

In the technology optimization in biomarkers, immune assays are the leaders of discovery machinery.